| GPBAR1 functions as gatekeeper for liver NKT cells and provides counterregulatory signals in mouse models of immune-mediated hepatitis M Biagioli, A Carino, C Fiorucci, S Marchianò, C Di Giorgio, R Roselli, ... Cellular and Molecular Gastroenterology and Hepatology 8 (3), 447-473, 2019 | 43 | 2019 |
| Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis A Carino, M Biagioli, S Marchianò, C Fiorucci, M Bordoni, R Roselli, ... Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2020 | 30 | 2020 |
| The bile acid receptor GPBAR1 modulates CCL2/CCR2 signaling at the liver sinusoidal/macrophage interface and reverses acetaminophen-induced liver toxicity M Biagioli, A Carino, C Fiorucci, S Marchianò, C Di Giorgio, M Bordoni, ... The Journal of Immunology 204 (9), 2535-2551, 2020 | 28 | 2020 |
| The aryl hydrocarbon receptor (AhR) mediates the counter-regulatory effects of pelargonidins in models of inflammation and metabolic dysfunctions M Biagioli, A Carino, C Fiorucci, G Annunziato, S Marchianò, M Bordoni, ... Nutrients 11 (8), 1820, 2019 | 24 | 2019 |
| Transcriptome analysis of dual FXR and GPBAR1 agonism in rodent model of NASH reveals modulation of lipid droplets formation A Carino, S Marchianò, M Biagioli, C Fiorucci, A Zampella, MC Monti, ... Nutrients 11 (5), 1132, 2019 | 24 | 2019 |
| Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction M Biagioli, S Marchianò, R Roselli, C Di Giorgio, R Bellini, M Bordoni, ... Biochemical Pharmacology 188, 114564, 2021 | 22 | 2021 |
| The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy A Carino, S Marchianò, M Biagioli, P Scarpelli, M Bordoni, C Di Giorgio, ... The FASEB Journal 35 (1), e21271, 2021 | 16 | 2021 |
| Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling S Marchianò, M Biagioli, R Roselli, A Zampella, C Di Giorgio, M Bordoni, ... Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2022 | 13 | 2022 |
| Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH S Marchianò, M Biagioli, E Morretta, C Di Giorgio, R Roselli, M Bordoni, ... Scientific reports 13 (1), 1602, 2023 | 12 | 2023 |
| Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling S Marchianò, M Biagioli, R Roselli, A Zampella, C Di Giorgio, M Bordoni, ... The FASEB Journal 36 (1), e22060, 2022 | 12 | 2022 |
| Discovery of a novel multi-strains probiotic formulation with improved efficacy toward intestinal inflammation M Biagioli, A Carino, C Di Giorgio, S Marchianò, M Bordoni, R Roselli, ... Nutrients 12 (7), 1945, 2020 | 12 | 2020 |
| GPBAR1 activation by C6-substituted hyodeoxycholane analogues protect against colitis SD Marino, C Finamore, M Biagioli, A Carino, S Marchianò, R Roselli, ... ACS Medicinal Chemistry Letters 11 (5), 818-824, 2020 | 10 | 2020 |
| Next-generation sequencing analysis of gastric cancer identifies the leukemia inhibitory factor receptor as a driving factor in gastric cancer progression and as a predictor of … C Di Giorgio, S Marchianò, E Marino, M Biagioli, R Roselli, M Bordoni, ... Frontiers in Oncology 12, 939969, 2022 | 8 | 2022 |
| GLP-1 mediates regulation of colonic ACE2 expression by the bile acid receptor GPBAR1 in inflammation M Biagioli, S Marchianò, R Roselli, C Di Giorgio, R Bellini, M Bordoni, ... Cells 11 (7), 1187, 2022 | 8 | 2022 |
| Identification of cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1 M Biagioli, A Carino, S Marchianò, R Roselli, C Di Giorgio, M Bordoni, ... Biochemical pharmacology 177, 113987, 2020 | 8 | 2020 |
| Combinatorial targeting of G‐protein‐coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug … M Biagioli, S Marchianò, C di Giorgio, R Roselli, M Bordoni, R Bellini, ... Hepatology 78 (1), 26-44, 2023 | 7 | 2023 |
| Discovery of a potent and orally active dual GPBAR1/CysLT1R modulator for the treatment of metabolic fatty liver disease S Fiorucci, P Rapacciuolo, B Fiorillo, R Roselli, S Marchianò, C Di Giorgio, ... Frontiers in Pharmacology 13, 858137, 2022 | 6 | 2022 |
| Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma C Di Giorgio, R Bellini, A Lupia, C Massa, M Bordoni, S Marchianò, ... Frontiers in Oncology 13, 1140730, 2023 | 5 | 2023 |
| Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders B Fiorillo, R Roselli, C Finamore, M Biagioli, C di Giorgio, M Bordoni, ... ACS omega 8 (6), 5983-5994, 2023 | 4 | 2023 |
| Repositioning mifepristone as a leukaemia inhibitory factor receptor antagonist for the treatment of pancreatic adenocarcinoma C Di Giorgio, A Lupia, S Marchianò, M Bordoni, R Bellini, C Massa, ... Cells 11 (21), 3482, 2022 | 4 | 2022 |
